Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Chinese Subjects with Moderate to Severe Plaque Psoriasis
NCT01646073Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2012
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Adalimumab with Placebo (2 arms). Primary endpoint: Proportion of Participants Achieving >= 75% Reduction in Psoriasis Area and Severity Index at 12 weeks. Started Aug 2012; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01646073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01646073.